As part of the FDA's rolling review of the biologics license application, Vertex expects to submit the first module to the regulator for potential accelerated approval before the end of 2025, and said ...
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $416.81, demonstrating a +2.01% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's ...
Is man's ability to perceive the form of objects inborn or must it be learned? Experiments indicate that it is innate but ...